Capitalizing on prescribing pattern variation to compare medications for type 2 diabetes

Value in Health

Volumn 17, Issue 8, 2014, Pages 854-862

  Prentice, Julia C ^a,b   Conlin, Paul R ^a,c   Gellad, Walid F ^d,e   Edelman, David ^f,g   Lee, Todd A ^h   Pizer, Steven D ^a,i  

^a VA BOSTON HEALTHCARE SYSTEM   (United States)

^b BOSTON UNIVERSITY SCHOOL OF MEDICINE   (United States)

^c HARVARD MEDICAL SCHOOL   (United States)

^d UNIVERSITY OF PITTSBURGH MEDICAL CENTER   (United States)

^e UNIVERSITY OF PITTSBURGH   (United States)

^f DURHAM VA MEDICAL CENTER   (United States)

^g DUKE UNIVERSITY SCHOOL OF MEDICINE   (United States)

^h UNIVERSITY OF ILLINOIS AT CHICAGO   (United States)

ⁱ NORTHEASTERN UNIVERSITY   (United States)

Author keywords

comparative effectiveness research; instrumental variables; provider prescribing variation; type 2 diabetes

Indexed keywords

GLIBENCLAMIDE; GLIMEPIRIDE; GLIPIZIDE; GLITAZONE DERIVATIVE; INSULIN; METFORMIN; PIOGLITAZONE; PRESCRIPTION DRUG; ROSIGLITAZONE; SULFONYLUREA DERIVATIVE; 2,4 THIAZOLIDINEDIONE DERIVATIVE; ANTIDIABETIC AGENT;

ACUTE HEART INFARCTION; AGED; AMBULATORY CARE; ARTICLE; CEREBROVASCULAR ACCIDENT; COMPARATIVE EFFECTIVENESS; DIABETES CONTROL; DIABETIC PATIENT; DRUG WITHDRAWAL; FEMALE; HOSPITALIZATION; HUMAN; INSULIN TREATMENT; LONG TERM SURVIVAL; MAJOR CLINICAL STUDY; MALE; MEDICARE; MONOTHERAPY; NON INSULIN DEPENDENT DIABETES MELLITUS; OBSERVATIONAL STUDY; PRESCRIPTION; QUASI EXPERIMENTAL STUDY; SELECTION BIAS; TIME TO TREATMENT; TREATMENT OUTCOME; UNITED STATES; VETERANS HEALTH; DIABETES MELLITUS, TYPE 2; DRUG COMBINATION; GOVERNMENT; MORTALITY; STATISTICS AND NUMERICAL DATA; TIME;

AGED; DIABETES MELLITUS, TYPE 2; DRUG THERAPY, COMBINATION; FEMALE; HOSPITALIZATION; HUMANS; HYPOGLYCEMIC AGENTS; MALE; MEDICARE; METFORMIN; SULFONYLUREA COMPOUNDS; THIAZOLIDINEDIONES; TIME FACTORS; UNITED STATES; UNITED STATES DEPARTMENT OF VETERANS AFFAIRS;

EID: 84915810012     PISSN: 10983015     EISSN: 15244733     Source Type: Journal    
DOI: 10.1016/j.jval.2014.08.2674     Document Type: Article

References (56)

1. A. Qaseem, L.L. Humphrey, and D.E. Sweet Oral pharmacologic treatment of type 2 diabetes mellitus: a clinical practice guideline from the American College of Physicians Ann Intern Med 156 2012 218 231
2. K.J. Lipska, and H.M. Krumholz Comparing diabetes medications: where do we set the bar? JAMA Intern Med 174 2014 317 318
3. N.F. Marko, and R.J. Weil The role of observational investigations in comparative effectiveness research Value Health 3 2010 989 997
4. R.R. Holman, S.K. Paul, and A. Bethel 10-Year follow-up of intensive glucose control in type 2 diabetes N Engl J Med 359 2008 1577 1589
5. P. Gaede, H. Lund-Andersen, H.H. Parving, and O. Pedersen Effect of a multifactorial intervention on mortality in type 2 diabetes N Engl J Med 358 2008 580 591
6. F. Zannad, W.G. Stough, and S.J. Pocock Diabetes clinical trials: helped or hindered by the current shift in regulatory requirements? Eur Heart J 33 2012 1049 1057
7. D. Preiss, N. Sattar, and J.J. McMurray A systematic review of event rate in clinical trials in diabetes mellitus: the importance of quantifying baseline cardiovascular disease history and proteinuria and implications for clinical trial design Am Heart J 161 2011 210 219
8. Food and Drug Administration. Guidance for Industry Diabetes mellitus - evaluating cardiovascular risk in new antidiabetic therapies to treat type 2 diabetes. Available from: http://www.fda.gov/downloads/Drugs/GuidanceComplianceRegulatoryInformation/Guidances/ucm071627.pdf. [Accessed July 21, 2014].
9. S.D. Pizer An intuitive review of methods for observational studies of comparative effectiveness Health Serv Outcomes Res Method 9 2009 54 68
10. M. McClellan, B.J. McNeil, and J.P. Newhouse Does more intensive treatment of acute myocardial infarction in elderly reduce mortality? JAMA 272 1994 859 866
11. J.D. Angrist, G.W. Imbens, and D.B. Rubin Identification of causal effects using instrumental variables J Am Stat Ass 434 1996 444 454
12. D. Staiger, and J. Stock Instrumental variables regression with weak instruments Econometrica 65 1997 557 586
13. Veterans Health Administration. About VHA. Available from: http://www.va.gov/health/aboutvha.asp/. [Accessed July 15, 2014].
14. United States General Accounting Office. Drug review process is standardized at the national level, but actions are needed to ensure timely adjudication of nonformulary drug requests. GAO 10-776. 2010. Available from: http://www.gao.gov/assets/310/308933.pdf. [Accessed July 31, 2014].
15. W.F. Gellad, C.B. Good, J.C. Lowe, and J.M. Donohue Variation in prescription use and spending for lipid-lowering and diabetes medications in the Veterans Affairs Healthcare System Am J Manag Care 16 2010 741 750
16. W.F. Gellad, M. Mor, and X. Zhao Variation in use of high-cost diabetes medications in the VA Healthcare System Arch Intern Med 172 2012 1608 1611
17. J.J. Doyle, S.M. Ewer, and T.H. Wagner Returns to physician human capital: evidence from patients randomized to physician teams J Health Econ 29 2010 866 882
18. Prentice JC, Conlin PR, Gellad WF, et al. Long term outcomes of analogue insulin compared to NPH for patients with type 2 diabetes. Am J Manag Care. In press.
19. M.A. Brookhart, J.A. Rassen, and P.S. Wang Evaluating the validity of an instrumental variable study of neuroleptics: can between-physician differences in prescribing patterns be used to estimate treatment effects? Med Care 45 Suppl. 2 2007 S116 S122
20. S. Schneeweiss, D.H. Solomon, and P.S. Wang Simultaneous assessment of short-term gastrointestinal benefits and cardiovascular risks of selective cyclooxygenase 2 inhibitors and nonselective nonsteroidal antiinflammatory drugs: an instrumental variable analysis Arthritis Rheum 54 2006 3390 3398
21. P.S. Wang, S. Schneeweiss, and J. Avorn Risk of death in elderly users of conventional vs. atypical antipyschotic medications N Engl J Med 353 2005 2335 2341
22. W.L. Bennett, N.M. Maruthur, and S. Singh Comparative effectiveness and safety of medications for type 2 diabetes: an update including new drugs and 2-drug combinations Ann Intern Med 154 2011 602 613
23. S.E. Inzucchi, R.M. Bergenstal, and J.B. Buse Management of hyperglycemia in type 2 diabetes: a patient-centered approach: Position statement of the American Diabetes Association (ADA) and the European Association for the Study of Diabetes (EASD) Diabetes Care 35 2012 1364 1379
24. VA/DOD Clinical Practice Guidelines. Management of diabetes mellitus (DM). 2010. Available from: http://www.healthquality.va.gov/guidelines/CD/diabetes/DM2010-FUL-v4e.pdf. [Accessed July 14, 2014].
25. K. Bognar, K.F. Bell, and D. Lakdawalla Clinical outcomes associated with rates of sulfonylurea use among physicians Am J Manag Care 19 2013 16 221
26. G.C. Alexander, N.L. Sehgal, R.M. Moloney, and R.S. Stafford National trends in treatment of type 2 diabetes mellitus, 1994-2007 Arc Intern Med 168 2008 2088 2094
27. L.C. Groop Sulfonylureas in NIDDM Diabetes Care 15 1992 737 754
28. C.L. Roumie, A.M. Hung, and R.A. Greevy Comparative effectiveness of sulfonylurea and metformin monotherapy on cardiovascular events in type 2 diabetes mellitus: a cohort study Ann Intern Med 157 2012 601 610
29. O'Riordan M. Sulfonylurea use increases all-cause mortality risk. In: European Association for the Study of Diabetes (EASD) 2013 Meeting. Barcelona, Spain, September 23-27, 2013.
30. F.Y. Hsiao, P.H. Hsieh, and W.F. Huang Risk of bladder cancer in diabetic patients treated with rosiglitazone or pioglitazone: a nested case-control study Drug Safety 36 2013 643 649
31. S.E. Nissen, and K. Wolski Effect of rosiglitazone on the risk of myocardial infarction and death from cardiovascular causes N Engl J Med 356 2007 2457 2471
32. D.M. Hynes, K. Koelling, and K. Stroupe Veterans' access to and use of Medicare and Veterans Affairs health care Med Care 45 2007 214 223
33. American Diabetes Association Standards of medical care for patients with diabetes mellitus Diabetes Care 26 Suppl. 2003 S33 S50
34. American Diabetes Association Standards of medical care in diabetes-2007 Diabetes Care 30 Suppl. 2007 S4 41
35. S.E. Aspinall, X. Zhao, and C.B. Good FDA warning and removal of rosiglitzone from VA national formulary Am J Manag Care 19 2013 748 758
36. United States Department of Veterans Affairs. VA National Formulary. Available from: http://www.pbm.va.gov/nationalformulary.asp. [Accessed July 10, 2014].
37. Action to Control Cardiovascular Risk in Diabetes Study Group Effects of intensive glucose lowering in type 2 diabetes N Engl J Med 358 2008 2545 2559
38. R.C. Turner, R.R. Holman, and C.A. Cull Intensive blood-glucose control with sulphonylureas or insulin compared with conventional treatment and risk of complications in patients with type 2 diabetes (UKPDS 33) Lancet 352 1998 837 853
39. The state of health care quality 2011. In: National Committee for Quality Assurance, ed., Continuous Improvement and the Expansion of Quality Measurement. Washington, DC: National Committee on Quality Assurance, 2011.
40. A. Elixhauser, C. Steiner, D.R. Harris, and R.M. Coffey Comorbidity measures for use with administrative data Med Care 36 1998 8 27
41. B.A. Young, E. Lin, and M.V. Korff Diabetes complications severity index and risk of mortality, hospitalization, and healthcare utilization Am J Manag Care 14 2008 15 24
42. AHRQ Quality Indicators - Guide to Prevention Quality Indicators: Hospital Admission for Ambulatory Care Sensitive Conditions. Rockville, MD: Agency for Health Care Research and Quality, 2001.
43. Agency for Health Care Research and Quality. Prevention quality indicators technical specifications- Version 4.5, May 2013. Available from: http://www.qualityindicators.ahrq.gov/Modules/PQI-TechSpec.aspx. [Accessed August 1, 2013].
44. N. Arnold, M.-W. Sohn, C. Maynard, and D.M. Hynes VA-NDI Mortality Merge Project. In: VA Information Resource Center VIReC Technical Report 2 2006 VA Information Resource Center Hines, IL
45. L.A. Petersen, S. Wright, S.L.T. Normand, and J. Daley Positive predictive value of the diagnosis of acute myocardial infarction in an administrative database J Gen Intern Med 14 1999 555 558
46. Y. Kyota, S. Schneeweiss, and R.J. Glynn Accuracy of Medicare claims-based diagnosis of acute myocardial infarction: estimating positive-predictive value on the basis of review of hospital records Am Heart J 148 2004 99 104
47. D.M. Reker, A.K. Rosen, and H. Hoenig The hazards of stroke case selection using administrative data Med Care 40 2002 96 104
48. J.V. Terza, A. Basu, and P.J. Rathouz Two-stage residual inclusion estimation: addressing endogeneity in health econometric modeling J Health Econ 27 2008 531 543
49. B. Efron Bootstrap methods: another look at the jackknife Ann Stat 7 1979 1 26
50. P.M. Grambsch, and T.M. Therneau Proportional hazards tests and diagnostics based on weighted residuals Biometrika 81 1994 515 526
51. G. Corrao, S.A. Romio, and A. Zambon Multiple outcomes associated with the use of metformin and sulphonylureas in type 2 diabetes: a population-based cohort study in Italy Eur J Clin Pharmacol 67 2011 289 299
52. American Diabetes Association Implications of the United Kingdom Prospective Diabetes Study Diabetes Care 25 Suppl. 2002 S28 S32
53. S.E. Kahn, S.M. Haffner, and M.A. Heise Glycemic durability of rosiglitazone, metformin, or glyburide monotherapy N Engl J Med 355 2006 2427 2443
54. Roy ASA. Stifling new cures: the true cost of lengthy clinical drug trials. Project FDA Report. 2012. Available from: http://www.manhattan-institute.org/pdf/fda-05.pdf. [Accessed January 12, 2014].
55. M.A. Brookhart, P.S. Wang, D.H. Solomon, and S. Schneeweiss Evaluating short-term drug effects using a physician-specific prescribing preference as an instrumental variable Epidemiology 17 2006 268 275
56. T.A. Stukel, E.S. Fisher, and D.E. Wennberg Analysis of observational studies in the presence of treatment selection bias: effects of invasive cardiac management on AMI survival using propensity score and instrumental variable methods JAMA 297 2007 278 285